| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | -409 | -409 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -9,183 | -9,295 |
| Cash and cash equivalents at beginning of period | 183,720 | - |
| Cash and cash equivalents at end of period | 174,537 | - |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)